Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04876651
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2021-05-03
Brief Title:
The Present Study Aims to Compare Patients Who Receive the Investigational Product 177Lu-DOTA-rosopatamab Plus Standard of Care in Comparison to Standard of Care Only
Sponsor:
Telix Pharmaceuticals Innovations Pty Ltd
Organization:
Telix Pharmaceuticals Innovations Pty Limited
Organization Data
Organization:
Telix Pharmaceuticals Innovations Pty Limited
Class:
INDUSTRY
Study ID:
177Lu-TLX591-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Telix Pharmaceuticals Innovations Pty Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None